Pluripotent Stem Cell-Derived Therapies for the Treatment of Hematological Cancers

Engineered cell therapies can effectively treat certain hematological cancers. However, conventional approaches using viruses to express targeting molecules on autologously derived cells can result in high manufacturing complexity and limited cancer targeting.

Our scientists developed a method for treating hematological cancers using engineered pluripotent stem cells¹⁵.

Pluripotent Stem Cell-Derived Therapies for the Treatment of Hematological Cancers is protected by a pending U.S. patent (with additional patents pending in other countries).

• Target hematological cancer using pluripotent stem cell-derived cytotoxic lymphocytes
• Combine with Factor’s Combined mRNA Cell Reprogramming & Gene Editing for streamlined manufacturing

• Combine with Factor’s Rapid Prototyping of GeneEditing Strategies for the Treatment of Cancer Technology to streamline the development of personalized medicines
• Combine with Factor’s Gene-Edited Allogeneic Cell Therapies Technology to create “off-the-shelf” therapies